Revisions to the Tumor, Node, Metastasis staging of lung cancer (8<sup>th</sup>edition): Rationale, radiologic findings and clinical implications

Kay, Fernando Uliana; Kandathil, Asha; Batra, Kiran; Saboo, Sachin S.; Abbara, Suhny; Rajiah, Prabhakar

doi:10.4329/wjr.v9.i6.269

Cited by 78 publications

(51 citation statements)

References 28 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study sample was stratified by stage (stage IIIA, stage IIIB, stage III not specified) and by histology (Squamous Cell Carcinoma, Adenocarcinoma, Other). Note that the study period predates the changes in NSCLC staging to include stage IIIC disease [5]. Descriptive methods were used to evaluate patient characteristics for the overall sample.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

This study examined real-world clinical outcomes such as progression-free survival (PFS), time to metastasis (TTM), overall survival (OS), and health-related quality of life (HRQOL) in patients with unresected stage III non-small cell lung cancer (NSCLC) treated in the community setting. A retrospective review of medical records extracted from 10 US community oncology practices was conducted. Eligible patients were adults diagnosed with stage III NSCLC from 1/1/2011 to 3/1/2016 without evidence of surgical resection within 6 months after stage III NSCLC diagnosis (index date). PFS, OS, and TTM were assessed from the index date, and were analyzed using Kaplan-Meier and Cox regression analyses. HRQOL was assessed for a subset of patients using a patient-reported measure, the 86-item Patient Care Monitor (PCM). Linear mixed models (LMM) were used to assess the impact of patient characteristics and change in PCM scores associated with progression. Among the sample of 478 patients, median PFS (95% confidence interval) was 10 months (9-11), median OS was 20 months (17-22), and median TTM was 30 months (23-45). Most patients (58.2%) experienced disease progression, which the LMM showed to be associated with significant worsening of physical symptoms and psychological states (p < 0.001). This study documented PFS and OS consistent with published literature. The majority of patients experienced disease progression, which was associated with worsening of HRQOL. These findings highlighted the need for better therapeutic options in patients with unresected stage III NSCLC with potential to improve patient outcomes and HRQOL.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The 5-year survival rate for stage IIIA is 36%, for stage IIIB is 26%, and for stage IIIC is 13% [4]. Stage IIIC is a newly defined group, which now includes patients with T3 or T4 disease, and N3 disease [5,6]. In the older staging system, patients who are now classified as stage IIIC would have been considered stage IIIB.…”

Section: Introductionmentioning

confidence: 99%

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The demographic information of the controls is also available in Table . The tumors were staged according to the 8th Union of International Control of Cancer (UICC) classification (Kay et al ., ).…”

Section: Methodsmentioning

confidence: 97%

Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non‐small cell lung cancer

et al. 2018

View full text Add to dashboard Cite

Lung cancer is the first leading cause of cancer deaths worldwide. Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer. Increasing evidence shows that long noncoding RNA (lncRNA) are capable of modulating tumor initiation, proliferation and metastasis. In the present study, we aimed to evaluate whether circulating lncRNA could be used as biomarkers for diagnosis and prognosis of NSCLC. Expression profiles of 14 lncRNA selected from other studies were validated in 20 pairs of tissues by quantitative real‐time PCR, and the dysregulated lncRNA thus identified were further validated in serum samples from two independent cohorts along with three tumor makers (CEA, CYFRA21‐1, and SCCA). Receiver‐operating characteristic analysis was utilized to estimate the diagnostic efficiency of the candidate lncRNA and tumor markers. Importantly, we observed an association between lncRNA expression and overall survival (OS) rate of NSCLC. The expressions of SOX2 overlapping transcript (SOX2OT) and ANRIL were obviously upregulated in NSCLC tissues and serum samples compared with normal controls (P < 0.01). Based on the data from the training set, we next used a logistic regression model to construct an NSCLC diagnostic panel consisting of two lncRNA and three tumor markers. The area under the curve of this panel was 0.853 (95% confidence interval = 0.804–0.894, sensitivity = 77.1%, specificity = 79.2%), and this was distinctly superior to any biomarker alone (all at P < 0.05). Similar results were observed in the validation set. Intriguingly, Kaplan–Meier analysis demonstrated that low expressions of SOX2OT and ANRIL were both associated with higher OS rate (P = 0.008 and 0.017, respectively), and SOX2OT could be used as an independent prognostic factor (P = 0.036). Taken together, our study demonstrated that the newly developed diagnostic panel consisting of SOX2OT, ANRIL, CEA, CYFRA21‐1, and SCCA could be valuable in NSCLC diagnosis. LncRNA SOX2OT and ANRIL might be ideal biomarkers for NSCLC prognosis.

show abstract

“…Globally, lung cancer remains the most common cause of cancer related death [1]. Compared to other Nordic countries, Denmark has a high lung cancer incidence and Danish lung cancer patients have historically had a high mortality [2].…”

Section: Introductionmentioning

confidence: 99%

Early death in Danish stage I lung cancer patients: a population-based case study

Christensen

Kejs²,

Jakobsen

et al. 2018

Acta Oncologica

View full text Add to dashboard Cite

Lung cancer with DR remains the most common CoD. Identifying and accordingly treating patients at risk for DR could potentially improve outcomes. Further studies of the predominantly male subgroup of patients who die of treatment complications are needed. Death from co-morbidity especially in patients with another cancer is a significant CoD and when assessing the quality of lung cancer care a competing event.

show abstract

Revisions to the Tumor, Node, Metastasis staging of lung cancer (8^thedition): Rationale, radiologic findings and clinical implications

Cited by 78 publications

References 28 publications

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non‐small cell lung cancer

Early death in Danish stage I lung cancer patients: a population-based case study

Contact Info

Product

Resources

About

Revisions to the Tumor, Node, Metastasis staging of lung cancer (8thedition): Rationale, radiologic findings and clinical implications

Cited by 78 publications

References 28 publications

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non‐small cell lung cancer

Early death in Danish stage I lung cancer patients: a population-based case study

Contact Info

Product

Resources

About

Revisions to the Tumor, Node, Metastasis staging of lung cancer (8^thedition): Rationale, radiologic findings and clinical implications